Loading news...
CareDx's President and CEO sold 19,480 shares over two days, totaling approximately $412,200 at an average price of $21.16 per share. The transaction reduced the CEO's direct holdings by 3.16%, leaving 597,405 shares directly owned post-sale.
19,480 shares directly sold for a total of ~$412,200 (weighted average price $21.16) across two transactions on Jan. 21 and Jan. 22, 2026. The sale represented 3.16% of direct holdings, reducing direct ownership from 616,885 to 597,405 shares (no indirect holdings involved).
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ —, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT on Tuesday, February 10, 2026. About CareDx CareDx.
CareDx, Inc. (NASDAQ: CDNA - Get Free Report) CEO John Walter Hanna, Jr. sold 10,156 shares of the firm's stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $21.05, for a total value of $213,783.80. Following the completion of the transaction, the chief executive officer owned
CareDx, Inc. (NASDAQ: CDNA - Get Free Report) has been given an average rating of "Hold" by the nine brokerages that are presently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among brokerages
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today reported preliminary, unaudited financial results for the fourth quarter and full year 2025. Preliminary Fourth Quarter 2025 Financial Results Revenue of approximately $108 million, an increase of 25% ye.
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a strategic collaboration with 10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, to establish ImmuneScape™, a multiomics research initiative designed by CareDx to eluci.
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On December 19, 2025, as an inducement material to acceptance of employment with CareDx, 39 new employees were awarded restricted stock units (RSUs) for an agg.
Shares of CareDx, Inc. (NASDAQ: CDNA - Get Free Report) have been given a consensus recommendation of "Hold" by the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) today provided notice of proposed settlement of derivative actions and settlement hearing. UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA JEFFREY EDELMAN, JAYSEN Case No. 3:25-cv-02036-TLT STEVENSON, and CHRISTIAN JACOBSEN, (Shareholder Derivative Action) Derivatively on Behalf of CareDx, Inc., SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF SHAREHOLDER DERIVATIVE ACTION Plaintiffs, v. GEORGE BICKERSTAFF,.
Geode Capital Management LLC boosted its holdings in shares of CareDx, Inc. (NASDAQ: CDNA) by 3.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,323,497 shares of the company's stock after buying an additional 43,074 shares during
The average of price targets set by Wall Street analysts indicates a potential upside of 28% in CareDx (CDNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Envestnet Asset Management Inc. boosted its holdings in CareDx, Inc. (NASDAQ: CDNA) by 17.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 22,489 shares of the company's stock after acquiring an additional 3,389 shares during the period. Envestnet Asset
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the publication of the third manuscript from Surveillance HeartCare Outcomes Registry (SHORE) in the Journal of Heart and Lung Transplantation (JHLT). The analysis, titled “Multimodal Molecular Testing Prov.
Aviva PLC increased its stake in shares of CareDx, Inc. (NASDAQ: CDNA) by 19.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 26,132 shares of the company's stock after buying an additional 4,317 shares during the quarter. Aviva PLC's
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On November 4, 2025, as an inducement material to acceptance of employment with CareDx, 49 new employees were awarded restricted stock units (RSUs) f.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new data presentations featuring CareDx technologies at American Society of Nephrology (ASN) Kidney Week 2025, underscoring the power of molecular biomarkers to advance transplant.
Progyny (NASDAQ: PGNY - Get Free Report) and CareDx (NASDAQ: CDNA - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership. Insider and Institutional Ownership 94.9% of Progyny shares are
CareDx, Inc ( CDNA ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Tina Jacobsen John Hanna - President, CEO & Director Nathan Smith - Chief Financial Officer Keith Kennedy - Chief Operating Officer Conference Call Participants Margarate Boeye - William Blair & Company L.L.C., Research Division Vidyun Bais - BTIG, LLC, Research Division William Bonello - Craig-Hallum Capital Group LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division Harrison Parsons - Stephens Inc., Research Division Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Operator Hello, and thank you for standing by.
While the top- and bottom-line numbers for CareDx (CDNA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.